TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Djokovic holds major stake in firm developing COVID drug: CEO
"He is one of the founders of my company we founded in June 2020," the chief executive of QuantBioRes, Ivan Loncarevic, told AFP.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Serbia's Novak Djokovic celebrates after winning against Uruguay's Pablo Cuevas during their men's singles second round tennis match on Day 5 of The Roland Garros 2021 French Open tennis tournament in Paris on June 3, 2021. (AFP/Martin Bureau )
S
erbian tennis star Novak Djokovic, recently deported from Australia due to his coronavirus vaccine status, is co-founder and majority shareholder of a biotech firm developing a COVID-19 treatment, the Danish company's CEO said Wednesday.
"He is one of the founders of my company we founded in June 2020," the chief executive of QuantBioRes, Ivan Loncarevic, told AFP.
According to information publicly available in the Danish business register, 34-year-old Djokovic and his wife, Jelena, together hold a stake of 80 percent in QuantBioRes, which employs a workforce of around 20 in Denmark, Slovenia, Australia and Britain.
"We aim to develop a new technology to fight viruses and resistant bacteria and we decided to use COVID as a showcase," Loncarevic said.
"If we succeed with COVID, we will succeed with other viruses."
QuantBioRes is planning to launch clinical trials in the UK in the summer, the CEO said.
The unvaccinated men's world number one flew out of Melbourne on Sunday after he failed in a last-gasp court bid to stay and play in the opening Grand Slam of the year, where he was targeting a record 21st major title.
His dramatic departure followed a protracted, high-stakes legal battle between the athlete and Australian authorities that cast a dark shadow over the tournament.
Contacted by AFP, Djokovic's spokesman declined to comment on the tennis star's stake in the Danish biotech firm.
